BioVie's NE3107 shows PD Phase 2a non-motor symptom improvement; AD Phase 3 misses significance but biomarker gains

BIOVIE INC.

PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.
PD: 26% of NE3107 patients had better morning motor scores vs 0% placebo (p=0.046); younger patients saw >6 point UPDRS advantage.
AD Phase 3 missed significance per protocol; NE3107 showed 68% slowing of decline on CDR-SB and 26% on ADAS-COG-12.
AD biomarkers: NE3107 associated with biological age deceleration -3.87 years (p=0.012), reduced fasting glucose and cholesterol.
Principal component analysis suggests NE3107 may realign metabolic inflammation; data presented at AD/PD 2024 in Lisbon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.